CASMED Receives Regulatory Clearance to Market FORE-SIGHT ELITE(R) Oximeters in Japan

CAS Medical Systems Logo

BRANFORD, Conn., June 26, 2014 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) (CASMED), a leader in medical devices for non-invasive patient monitoring, announces receipt of regulatory clearance to market the Company's FORE-SIGHT ELITE® Cerebral Oximeters in Japan.

Under a previously announced exclusive distribution agreement for Japan with Century Medical Inc. (CMI), CASMED will soon begin shipping FORE-SIGHT ELITE oximetry products to CMI and expects that CMI will begin making the product available to customers in July.

"We are pleased to offer our world-class FORE-SIGHT ELITE technology to clinicians and their patients in the world's second largest medical market," said Thomas Patton, CASMED's President and CEO. "Although the FORE-SIGHT technology has been available in the United States and elsewhere since 2007, this approval marks the first time FORE-SIGHT will be available in Japan. Importantly, there appear to be many Japanese physicians who are keenly interested in evaluating our technology for incorporation into their clinical practice. With CMI as our committed distribution partner and with our product's industry-leading accuracy, we believe that revenues in Japan may soon be second only to those in the United States."

"A key component of our Company's growth strategy is expanding international distribution of FORE-SIGHT, and the launch of FORE-SIGHT ELITE oximetry and the hiring of Karen Harris-Coleman as Vice President of International Sales were the catalysts to advance that strategy," said Brian Wagner, CASMED's Chief Commercial Officer. "With Japan we now have approvals and high-quality distributors in the world's top six medical markets and expect to open additional markets for FORE-SIGHT throughout the world."

About CASMED® – Monitoring What's Vital

CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring that are vital to patient care. The Company's FORE-SIGHT Absolute Cerebral Oximetry technology provides highly accurate, non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation. Direct monitoring of tissue oxygenation provides a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service.
For further information regarding CASMED, visit the Company's website at

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks detailed in the Company's Form 10-K for the year ended December 31, 2013, and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will", and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

Company Contact
CAS Medical Systems, Inc.
Jeffery A. Baird
Chief Financial Officer
(203) 315-6303
Investor Contact
Bruce Voss
(310) 691-7100

Source:CAS Medical Systems, Inc.